Novel Epitopes of Bacillus anthracis Lethal Factor for Development of Diagnostics and Therapeutics

CDC researchers have characterized epitopes of Bacillus anthracis Lethal Factor (LF), a critical component of the B. anthracis lethal toxin. These epitopes may allow for development of therapeutics for the treatment or prevention of B. anthracis infection. They may also allow screening for B. anthracis LF in a sample and development of a peptide anthrax vaccine.

Potential Commercial Applications: Competitive Advantages:
  • Diagnostic tests assessing active Lethal Factor in a sample
  • Anthrax neutralizing therapeutics and vaccines for B. anthracis
  • Biodefense, biosecurity
  • Potentially faster, lower-input assay compared to current Edema Factor detection methods
  • Easily adaptable for high-throughput screening of numerous specimens

Related Inventoion(s):

Conrad Quinn (CDC)
Anne Boyer (CDC)
Jason Goldstein (CDC)
Dennis Bagarozzi (CDC)

Intellectual Property:
US Application No. 61/699,738
PCT Application No. PCT/US2013/059179

Licensing Contact:
Tara Kirby , Ph.D.
NIH Office of Technology Transfer
Phone: 301-435-4426

OTT Reference No: E-210-2013/0

Updated: Dec-23-2013